Skip to content

The effect of Bromelain on episiotomy pain and wound healing

The evaluation of oral Bromelain (pineapple) on episiotomy pain and wound healing in primiparus women

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT138810112952N1
Enrollment
100
Registered
2010-02-27
Start date
2009-06-05
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Episiotomy. Complications of the puerperium, not elsewhere classified

Interventions

Intervention 1: Bromelain, 100mg (one tablet), starting from 2 hrs after delivery, three tims daily for six days. Intervention 2: Placebo, one tablet, from 2 hrs after delivery, three times daily for
Treatment - Drugs
Placebo
Bromelain, 100mg (one tablet), starting from 2 hrs after delivery, three tims daily for six days
Placebo, one tablet, from 2 hrs after delivery, three times daily for six days

Sponsors

Research center of Jondishapur University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age between 18 to 35 years, Gestational age between 37 to 42 weeks, single pregnancy, cephalic presentation, Iranian nationality, residence in Ahvaz, Normal vaginal delivery, newborn Weight between 2500 to 4000 grams, medio-lateral episiotomy with 4-3 cm length, Education level at least the fifth grade, body mass index: 19/6-26, cervical dilation 3-5 cm Exclusion criteria: Diseases affecting wound healing (diabetes, kidney disease, anemia, liver diseases, cystocele or anxiety disorders), smoking and drug abuse, consumption of drugs affecting wound healing (glucocorticoids, anti-coagulatives, immune system suppressants, antibiotics or chemotherapy agents), abortion, premature rupture of membranes, having symptoms indicative of infection, anemia, rectum and vulva lesions, abnormal bleeding after childbirth, hematoma in the perineal operation, newborn anomaly, dead baby, abnormal first, second or third delivery stage

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Pain. Timepoint: 2 hrs after delivery, 24 hrs after delivery, 1 hr after consumption of initial dose, 3th, 7th, and 14th day after delivery. Method of measurement: VAS scale.

Secondary

MeasureTime frame
Wound healing. Timepoint: 3th, 7th, and 14th day after delivery. Method of measurement: REEDA scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSamira Golozar

Ahwaz Jondishapoor University of Medical Sciences

golezar80@yahoo.com+98 83 7222 4977

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026